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Just because one sequences the whole exome or whole
genome doesn’t mean the variant responsible for the
phenotype of interest jumps out with a red flag waving.
One needs to carefully filter and curate the data to sort
through the thousands of variants that differ from the
human reference sequence. Even so, the causative variant
might remain undeciphered. This led Zemojtel et al. to
the question: could a machine sort variation better than
a person? They developed an algorithm called PhenIX
that ranks variants according to how well the patient
phenotype matches information previously described for
the relevant Mendelian disease. To ensure there was infor-
mation to put into the algorithm, they limited sequence
efforts to the disease-associated genes, rather than the
whole exome. In a prospective sample of 40 individuals
without a diagnosis, PhenIx identified the causative
variants in 11. This is not going to put geneticists out
of business; a key to the success of the algorithm is a
detailed clinical evaluation of the patient before the
analysis and examination of the top-ranked variants in
the output.
Zemojtel et al. (2014). Sci. Trans. Med. 6, 252ra123.
Mining for Mosaicism
In individuals with somatic mosaicism, the relevant
variant is unlikely to be found at the same level in all tis-
sues, if it is widespread in the body at all. This makes
genetic testing tricky, particularly when the affected
tissues are difficult—or even impossible—to get from a
patient. Such is the case with some cerebral cortical mal-
formations, the phenotype that was recently examined
by Jamuar et al. Although sometimes resulting from
constitutional mutations, these neurodevelopmental is-
sues can also stem from mosaic mutations, which led
the authors to assess whether this mosaicism could be
detected through high-depth next-generation sequencing
(e.g., 2003) of leukocyte-derived DNA. Indeed, variants
likely to be relevant to the brain phenotype were found
in the blood of a number of individuals—mosaicism
accounted for 30% of the cases in which suspected path-
ogenic variants were found. Some of these changes had
been missed by Sanger sequencing and/or by exome
sequencing, adding further caveats to the meaning of a
‘‘negative’’ genetic test result.
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The AmericPopulating the Arctic
People have lived in the Arctic areas of North America for
thousands of years. Indeed, artifacts left behind by these
people indicate that there have been multiple distinct
Arctic cultures. How exactly some of these groups relate
to each other as well as to other Native American popu-
lations has been a bit of a mystery. To provide insight,
Raghavan et al. obtained whole-genome or mitochondrial
DNA sequences from more than 100 ancient samples and
compared them to each other as well as to modern-day
individuals from Arctic populations. Their results suggest
that the Paleo-Eskimo cultures were established after a sin-
gle migratory wave from Siberia that was independent of
the ones that established the Native American and Inuit
populations. Over a genetic continuum existing for thou-
sands of years, rich cultural differences developed in the
isolated group without major in-flow via additional migra-
tions. In fact, the movement of the Thule culture —the
precursor to the modern Inuit population—into the Arctic
replaced the Paleo-Eskimos about 700 years ago.
Raghavan et al. (2014). Science 345, 1255832.
Gene Scramble
Particularly given the excess of rare genetic variation in the
human population, it can be difficult to discern the biolog-
ical outcome of a variant that has rarely, or even never,
before been reported. Variants can’t each possibly be
functionally assessed—or can they? Jay Shendure’s group
has co-opted the CRISPR/Cas9 system to systematically
create all possible single-nucleotide variants in a stretch
of sequence, then coupled the editing system with high-
throughput functional readouts to assess the outcome.
As a first attempt, they systematically edited exon 18 of
BRCA1 and estimated the effect of each variant with mea-
surements of the relative amounts of cDNA and gDNA to
gauge transcript abundance. In a second example, they
edited the essential gene DBR1 and assessed functional
impact through relative effects on cell growth. Theoreti-
cally, one could do this for many different genes; finding
the right scalable functional assay is key to making it
worthwhile.
Findlay et al. (2014). Nature 513, 120–123.
Middling
Behaving just as we expect for a complex trait, the genetic
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(T2D) is either rare and makes a strong contribution to
risk or common and has a weak effect on risk. Majithia
et al. wondered whether there might be genetic variation
that falls somewhere in the middle, a question that has
been difficult to study. Because it is already known to
contribute to both the rare, syndromic and the common
forms of T2D, they focused on PPARg, the gene for the
peroxisome proliferator-activated receptor gamma, a regu-
lator of adipocyte differentiation. PPARg sequence from
more than 9,000 individuals with T2D and 10,000 controls
yielded 53 nonsynonymous variants. As a whole, the rare
missense variants they uncovered were not significantly344 The American Journal of Human Genetics 95, 343–344, Octoberassociated with diabetes, and in fact, most had never
been described before, leading to a research dead-end.
That is, until the researchers developed a high-throughput
assay of adipocyte differentiation through which they
could assess the functionality of the missense PPARg
variants. Going back to the case-control data, they found
that when they limited their association study to the
reduced-function variants, a signal jumped out; carrying
one of these variants led to a seven-fold increase in T2D
risk, exactly the type of moderate risk variant they hoped
to find.
Majithia et al. (2014). PNAS 111, 13127–13132.This Month in Our Sister JournalBroadening the View of Ribosomopathies
When one approaches clinical genetic testing with a
gene-by-gene approach, as it has traditionally been
done, the selection of genes to be sequenced is limited
by the phenotypes that have already been described for
a gene; if the patient’s phenotype doesn’t overlap with
what has been reported, there is no reason to sequence
that gene. With the incorporation of gene panels and
exome sequencing into the clinic, one can find unex-
pected variation in genes that wouldn’t have been
likely candidate genes. Brooks et al. provide an example
in their recent analysis of a family with members affected
by an X-linked form of microcephaly, growth retardation,and seizures. An X-linked intellectual disability gene
sequencing panel revealed a missense change in the 60S
ribosomal protein L10 (RPL10), a gene that prior to this
report had only been implicated in autism. Modeling
the change in zebrafish supports the fact that the variant
is pathogenic because it cannot rescue the microcephaly
phenotype in fish that have reduced rpl10 expression.
Although it is still puzzling why a gene involved in a
central biological process has a tissue-restricted pheno-
type, the experiments in fish suggest that embryos treated
with a morpholino to rpl10 have increased apoptosis in
their forebrains.
Brooks et al. (2014). Genetics 198, 723–733.2, 2014
